Using Radioactive Material Patents (Class 435/35)
  • Patent number: 9052310
    Abstract: A universal sensor fabrication approach, molecular substrate imprinting technique, which utilizes the interaction between molecular building blocks and the surface of a transducer to develop specific molecular recognition cavities has been established. Integration of molecular recognition cavities with the surface of a nanoscale transducer will result in a nano-tunneling effect that takes place which will provide a sensor or a device that exhibits new properties not already exhibited by either the molecular recognition cavities on a bulk transducer or the nanotransducer material. One of the new properties of this nano-tunneling effect is that a universal potentiometric molecular sensor can be fabricated and used to detect any compounds, whether they are ions or molecules, with enhanced selectivity, sensitivity, and stability when molecular recognition cavities or elements are integrated on the surface of a nanoscale transducer.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: June 9, 2015
    Inventor: Yanxiu Zhou
  • Publication number: 20150064111
    Abstract: The invention relates to compounds and use thereof in the diagnosis and/or in treatment of medical disorders. In some embodiments, the compounds may be used for detecting a cancer. The compound may include a di-acid moiety. In some embodiments the di-acid moiety comprises a di-carboxylic acid and in some embodiments the di-acid moiety comprises a di-tetrazole.
    Type: Application
    Filed: April 3, 2013
    Publication date: March 5, 2015
    Applicant: APOSENSE LTD.
    Inventors: Joel M. Van Gelder, Menashe Levy, Mirit Argov, Miri Ben-Ami, Ilan Ziv
  • Patent number: 8906610
    Abstract: Herein is described methods for a high-sensitivity means to measure the incorporation of stable isotope labeled substrates into RNA following stable isotope probing experiments (SIP). RNA is hybridized to a set of probes such as phylogenetic microarrays and isotope incorporation is quantified such as by secondary ion mass spectrometer imaging (NanoSIMS).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: December 9, 2014
    Assignee: The Regents of the University of California
    Inventors: Eoin L. Brodie, Todd Z. DeSantis, Ulas Karaoz, Gary L. Andersen
  • Patent number: 8877459
    Abstract: Identification of infectious pathogens, particularly viruses, bacteria and other microorganisms is effected with a method whereby pathogens of acute infections can be identified, without first culturing them in external nutrient media, by mass spectrometric measurement of their protein profiles obtained from pathogens directly precipitated from body fluid into pellets by centrifuging. With this method, pathogens which cause acute infections can be identified in less than one hour.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: November 4, 2014
    Assignee: Bruker Daltonik GmbH
    Inventor: Ulrich Weller
  • Publication number: 20140228248
    Abstract: The present invention provides, inter alia, methods for detecting whether a subject has an infection. These methods include (a) incubating a test sample from a subject suspected of having an infection with a labeled molecule, such as a labeled nucleoside analog, that is preferentially incorporated into a pathogenic microorganism for a period of time sufficient for the pathogenic microorganism to incorporate the labeled molecule; (b) removing any unincorporated labeled molecule from the test sample; and (c) detecting the labeled molecule within the pathogenic microorganism, if any, in the test sample, wherein the presence of labeled molecule within the pathogenic microorganism indicates that the subject has an infection.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 14, 2014
    Applicant: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh Saha, Chetan Bettegowda, David Tung
  • Publication number: 20130130309
    Abstract: HPLC-based quality control systems to perform quality control testing on a radiopharmaceutical solution shortly after synthesis. An HPLC-based quality control system makes efficient use of sample volume and is compatible with a variety of radioisotopes and radiopharmaceutical compounds. In several embodiments, the automated nature of an HPLC-based quality control system allows for quality control tests to be conducted quickly and with minimal impact on user workflow. When used as part of an integrated PET biomarker radiopharmaceutical production system, the present general inventive concept permits a manufacturer to produce product and conduct quality control tests with lower per dose costs.
    Type: Application
    Filed: April 13, 2012
    Publication date: May 23, 2013
    Applicant: ABT MOLECULAR IMAGING INC
    Inventors: Ronald Nutt, Antony M. Giamis, Aaron McFarland
  • Publication number: 20130034496
    Abstract: The present invention relates to positron emission tomography tracers and methods of using these tracers.
    Type: Application
    Filed: August 2, 2012
    Publication date: February 7, 2013
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventor: Amnon Kohen
  • Publication number: 20110124005
    Abstract: Disclosed is a reagent for detecting an abnormal cell in the cervix of uterus, which can detect an abnormal cell contained in a biological sample that contains cells collected from the cervix of uterus. The reagent comprises a dye represented by general formula (I).
    Type: Application
    Filed: July 27, 2009
    Publication date: May 26, 2011
    Applicant: SYSMEX Corporation
    Inventors: Masakatsu Morita, Akinori Kawai, Yukio Tsujino
  • Patent number: 7910698
    Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: March 22, 2011
    Assignee: Schering Corporation
    Inventors: Scott Altmann, Xiaorui Yao, Kim Ann O'Neill, Brian E. Hawes
  • Patent number: 7824883
    Abstract: Method and apparatus for the detection of microbes in liquids, in air and on non-living surfaces in which samples are exposed to frequency-modulated electromagnetic radiation of specific energies capable of exciting various metabolites, cofactors and cellular and spore components, with the microbial cells to be sampled (and more specifically the excited metabolites, cofactors and/or other cellular components) contained therein emit fluorescence that can be measured that is similarly frequency-modulated provided that the excitation frequencies are longer than the fluorescence lifetime of the excited intrinsic microbial fluorophore.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: November 2, 2010
    Inventors: Linda S. Powers, Christopher R. Lloyd
  • Patent number: 7807403
    Abstract: A method for determining whether a microorganism produces an AmpC ?-lactamase is disclosed in which a culture of a microorganism suspected of producing a ?-lactamase that inactivates a ?-lactam-containing antibiotic is admixed with an effective amount of each of i) a ?-lactam-containing antibiotic, ii) a ?-lactamase inhibitor to which AmpC ?-lactamase is resistant, and iii) a permeabilizing agent for the microorganism present in a non-growth-inhibiting microorganism-permeabilizing amount to form an assay culture. That assay culture in maintained under appropriate culture conditions and for a time period sufficient to determine the interaction of the microorganism with the AmpC ?-lactamase resistant inhibitor and antibacterial compound, and thereby determine the presence of an AmpC ?-lactamase, wherein a positive test indicates the presence of an AmpC ?-lactamase.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: October 5, 2010
    Assignee: Creighton University
    Inventors: Jennifer A. Black, Kenneth S. Thomson
  • Patent number: 7718392
    Abstract: The present invention provides a method of determining the antibiotic susceptibility of a microorganism comprising the following steps. First, a culture of the microorganism whose susceptibility is to be determined is admixed with an antibiotic to which susceptibility is to be assayed, and a permeabilizing agent for the microorganism present in a non-growth-inhibiting microorganism-permeabilizing effective amount to form an assay culture. Next, the assay culture is incubated under appropriate culture conditions and for a time sufficient to determine the susceptibility of the microorganism to the antibiotic.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: May 18, 2010
    Assignee: Creighton University
    Inventors: Jennifer A. Black, Ellen S. Moland, Kenneth Thomson
  • Patent number: 7645594
    Abstract: A method of staining bacteria comprises: working a polymethine dye on a sample in the presence of a substance capable of reducing nitrite ions to stain bacteria in the sample. A method of detecting bacteria comprises the following steps of: (1) working a polymethine dye on a sample by a method as described above to stain bacteria in the sample, (2) introducing the thus treated sample into a detecting part of a flow cytometer and irradiating cells of the stained bacteria one by one with light to measure scattered light and fluorescent light emitted from each of the cells; and (3) discriminating the bacteria from other components in accordance with an intensity of a scattered light signal and an intensity of a fluorescent light signal or a pulse width reflecting the length of particles to count the bacteria.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: January 12, 2010
    Assignee: Sysmex Corporation
    Inventors: Yasuhiro Sakai, Yasuyuki Kawashima, Junya Inoue, Yoshiro Ikeuchi
  • Publication number: 20100003715
    Abstract: A sample under test containing non-live and/or live particulates is subject to optical excitation on a single particle-by-particle basis or as a small group of particulates sufficient to induce a subsequent fluorescence emission that is observed for a selected period of time by a sensor, typically a photomultiplier tube. The output of the sensor is representative of the intensity or amplitude of the fluorescence emission while the decrease in that intensity or amplitude with time is representative of the decay rate of the fluorescence emission. Those particulates exhibiting a decay rate “faster” than a threshold decay rate, which is determined empirically for the class of biological agents of interest, are identified as living while those particulates exhibiting decay rate “slower” than a threshold decay rate, which is also determined empirically for the class of biological agents of interest, are identified as a non-live interferant.
    Type: Application
    Filed: December 21, 2004
    Publication date: January 7, 2010
    Inventor: Francesco Pellegrino
  • Patent number: 7452691
    Abstract: The present invention provides a method of detecting production of antibiotic-inactivating factor and for determining the antibiotic susceptibility of a microorganism comprising the following steps, a culture of the microorganism suspected of producing inactivating factors and/or whose susceptibility is to be determined is admixed with an antibiotic to which susceptibility is to be assayed, and a permeabilizing agent for the microorganism present in a non-growth-inhibiting microorganism-permeabilizing effective amount to form an assay culture. The assay culture is incubated under appropriate culture conditions and for a time sufficient to determine production of antibiotic-inactivating factors and/or the susceptibility of the microorganism to the antibiotic.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: November 18, 2008
    Assignee: Creighton University
    Inventors: Jennifer A. Black, Ellen S. Moland, Kenneth Thomson
  • Publication number: 20080260637
    Abstract: A method of detecting presence or absence of prostate cancer in a subject, both in vivo and ex vivo is disclosed. The method comprises analyzing mitochondria or a mitochondrial component in at least one prostate cell of the subject, whereby mitochondria an alteration in quantity and or characteristic is indicative of the presence or absence of the prostate cancer in the subject.
    Type: Application
    Filed: November 16, 2005
    Publication date: October 23, 2008
    Inventor: Dalia Dickman
  • Patent number: 7407775
    Abstract: A substrate which can be used for the direct identification of pathogenic bacteria belonging to the genus Listeria by detecting an esterase activity other than Phosphatidyl Inositol-specific Phospholipase C (PI-PLC), an esterase which is specific to the species Listeria monocytogenes. The use of two substrates, one as described above and the other specific for all or some members of the genus Listeria, and a reaction medium containing such a substrate or such a combination of substrates are disclosed. An identification method which exploits such culture media is also disclosed. The invention is particularly applicable in the field of diagnosis.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: August 5, 2008
    Assignee: Biomerieux S.A.
    Inventors: Céline Roger-Dalbert, Laurence Barbaux
  • Patent number: 7364874
    Abstract: Van A and Van B vancomycin resistant enterococci detection media as well as a method of selectively detecting Van A and Van B vancomycin resistant enterococci clinically important in vancomycin resistant enterococci from testing microorganisms or specimens using the media. The media for selectively detecting Van A and Van B VRE from testing microorganisms and specimens are media where enterococci can grow where vancomycin, D-cycloserine and D-lactate are added. Preferably 32-256 ?g/ml of vancomycin, 1-64 ?g/ml of D-cycloserine, and 0.025-0.8 mol/l of sodium lactate are added to culture medium where enterococci can grow.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: April 29, 2008
    Assignee: Tokyo Women's Medical University
    Inventors: Kyoichi Totsuka, Ken Kikuchi, Yutaka Uzawa
  • Patent number: 7341849
    Abstract: This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on. As one of the methods for obtaining the G protein-coupled receptor proteins of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: March 11, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
  • Patent number: 7335485
    Abstract: The present invention provides a method of determining the antibiotic susceptibility of a microorganism comprising the following steps. First, a culture of the microorganism whose susceptibility is to be determined is admixed with an antibiotic to which susceptibility is to be assayed, and a permeabilizing agent for the microorganism present in a non-growth-inhibiting microorganism-permeabilizing effective amount to form an assay culture. Next, the assay culture is incubated under appropriate culture conditions and for a time sufficient to determine the susceptibility of the microorganism to the antibiotic.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: February 26, 2008
    Assignee: Creighton University
    Inventors: Jennifer A. Black, Ellen S. Moland, Kenneth Thomson
  • Patent number: 7291480
    Abstract: A method for determining whether a microorganism produces an AmpC ?-lactamase is disclosed in which a culture of a microorganism suspected of producing a ?-lactamase that inactivates a ?-lactam-containing antibiotic is admixed with an effective amount of each of i) a ?-lactam-containing antibiotic, ii) a ?-lactamase inhibitor to which AmpC ?-lactamase is resistant, and iii) a permeabilizing agent for the microorganism present in a non-growth-inhibiting microorganism-permeabilizing amount to form an assay culture. That assay culture in maintained under appropriate culture conditions and for a time period sufficient to determine the interaction of the microorganism with the AmpC ?-lactamase resistant inhibitor and antibacterial compound, and thereby determine the presence of an AmpC ?-lactamase, wherein a positive test indicates the presence of an AmpC ?-lactamase.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: November 6, 2007
    Inventors: Jennifer A. Black, Kenneth S. Thomson
  • Patent number: 7270978
    Abstract: A substrate which can be used for the direct identification of pathogenic bacteria belonging to the genus Listeria by detecting an esterase activity other than Phosphatidyl Inositol-specific Phospholipase C (PI-PLC), an esterase which is specific to the species Listeria monocytogenes. The use of two substrates, one as described above and the other specific for all or some members of the genus Listeria, and a reaction medium containing such a substrate or such a combination of substrates are disclosed. An identification method which exploits such culture media is also disclosed. The invention is particularly applicable in the field of diagnosis.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: September 18, 2007
    Assignee: Biomerieux S.A.
    Inventors: Céline Roger-Dalbert, Laurence Barbaux
  • Patent number: 7267962
    Abstract: The present invention provides a method of determining the antibiotic susceptibility of a microorganism comprising the following steps. First, a culture of the microorganism whose susceptibility is to be determined is admixed with an antibiotic to which susceptibility is to be assayed, and a permeabilizing agent for the microorganism present in a non-growth-inhibiting microorganism-permeabilizing effective amount to form an assay culture. Next, the assay culture is incubated under appropriate culture conditions and for a time sufficient to determine the susceptibility of the microorganism to the antibiotic.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: September 11, 2007
    Assignee: Creighton University
    Inventors: Jennifer A. Black, Ellen S. Moland, Kenneth S. Thomson
  • Patent number: 7101719
    Abstract: Disclosed is a method for the measurement of a cellular process, or for the measurement of the effect of a test compound on a cellular process, in one or more different populations of cells. The method comprises providing separate samples of one or more different populations of cells adhering to support particles, the support particles comprising a scintillant substance and being adapted for cell growth. In one embodiment, different samples of cells are introduced into separate reaction vessels in a fluid medium, together with a reagent labelled with a radioisotope, in the presence or the absence of the test compound, under conditions so as to cause a portion of said radiolabelled reagent to become associated with the cells. In another embodiment, multiparameter analysis may be performed to determine the effect of a test compound on a cellular process using two or more different cell populations present in the same well.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: September 5, 2006
    Assignee: GE Healthcare Limited
    Inventors: Gerard Bernard O'Beirne, Rahman Aziz Ismail, Nicholas Thomas
  • Patent number: 7015012
    Abstract: The present invention is based, in part, on the discovery of methods for identifying compounds that mediate (by promoting or inhibiting) protein-protein interaction (e.g., aggregation, dimerization, or other physiologically significant association). Compounds that mediate such interaction, which are also within the scope of the invention, can be used to treat Alzheimer's disease, disorders associated with expanded CAG repeats (such as Huntington's disease), and disorders in which polyglutamine-containing transcription factors or coactivators are undesirably active (e.g., disorders associated with homodimerization of jun or hexamerization of p53.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: March 21, 2006
    Assignee: Massachusetts Institute of Technology
    Inventors: David E. Housman, Aleksey G. Kazantsev
  • Patent number: 6968063
    Abstract: A casino gaming machine includes a speaker structured to produce a game audio output having a volume, an ambient noise level (ambient noise level) detector structured to detect an ambient noise level proximate the gaming machine, and an dynamic volume controller configured to regulate the volume of the game audio output in relation to a detected ambient noise level. The gaming machine can produce a plurality of game audio outputs, wherein the game audio output volumes can be differentially adjusted in relation to a detected ambient noise level. Differential volume adjustment can be on the basis of a parameter, such as sound output class.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: November 22, 2005
    Assignee: Acres Gaming Incorporated
    Inventor: Scott Boyd
  • Patent number: 6955886
    Abstract: The invention provides a scintillation proximity assay for detecting peptidoglycan synthesis. The assay is especially suitable for high throughput screening of compounds affecting peptidoglycan synthesis.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: October 18, 2005
    Assignee: AstraZeneca AB
    Inventors: Sunita Desousa, Dwarakanath Prahlad
  • Patent number: 6908741
    Abstract: Provided are methods to detect of modulators of the Receptor for Advanced Glycated Endproducts (RAGE). The invention comprises a method for detection of RAGE modulators comprising: adsorbing a RAGE ligand onto a solid surface; adding a compound of interest and a protein comprising RAGE or fragment thereof, to the preadsorbed ligand; adding an antibody which binds to RAGE or fragment thereof and a secondary antibody which binds to the anti-RAGE antibody; measuring the secondary antibody bound to the anti-RAGE antibody; and comparing the amount of RAGE bound to the ligand in the presence of varying amounts of the compound of interest. In an embodiment, the fragment of RAGE is sRAGE. In one aspect, the invention use of compounds detected by the method for treatment of AGE-related syndromes including complications associated with diabetes, kidney failure, lupus nephritis or inflammatory lupus nephritis, amyloidoses, Alzheimer's disease, cancer, inflammation, and erectile dysfunction.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: June 21, 2005
    Assignee: TransTech Pharma, Inc.
    Inventor: Manouchehr M. Shahbaz
  • Patent number: 6855513
    Abstract: The invention provides methods for identifying a modulator of quorum sensing signaling in bacteria, and for identifying a quorum sensing controlled gene in bacteria. In addition, the invention provides quorum sensing controlled genetic loci in Pseudomas aeruginosa. Novel indicator strains and vectors for engineering the strains for use in the method of the invention are also provided.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: February 15, 2005
    Assignees: University of Iowa Research Foundation, Vertex Pharmaceuticals (San Diego) LLC
    Inventors: Marvin Whiteley, Kimberly M. Lee, E. Peter Greenberg, Ute Muh
  • Patent number: 6808899
    Abstract: This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on. As one of the methods for obtaining the G protein-coupled receptor proteins of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: October 26, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
  • Publication number: 20040166557
    Abstract: An isolation plating medium for the identification of Salmonella bacteria in a sample containing a plurality of different bacteria comprising a mixture of a carbohydrate capable of being a metabolic source for Salmonella bacteria and supporting colonies of Salmonella bacteria, a pH indicator dye that changes the color of the plating medium to a first color different from the color of the medium responsive to a change in the pH of the medium, a first substrate that does not react with Salmonella bacteria and injects color into the medium of a second color responsive to the presence of beta-galactosidase, the second color contrasting with the first color and the color of the medium, a second substrate that does not react with Salmonella bacteria and injects color into the medium of substantially the same color as the second color responsive to the presence of beta=galactosidase, and an ingredient for thickening the mixture in sufficient quantity to solidify the mixture.
    Type: Application
    Filed: February 23, 2004
    Publication date: August 26, 2004
    Inventor: Lawrence Restaino
  • Patent number: 6773892
    Abstract: Methods for detecting schizophrenia or related neuropsychiatric disorders based on modifications of the contribution of the D4 receptor to phospholipid methylation levels are described herein. Individuals with schizophrenia or related neuropsychiatric disorders have a deficiency in phospholipid methylation activity compared with normal individuals. Methods for screening therapeutic processes or agents for use in treatment of schizophrenia or related neuropsychiatric disorders are also described.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: August 10, 2004
    Assignee: Northeastern University
    Inventor: Richard C. Deth
  • Patent number: 6653135
    Abstract: An assay to determine the specific expression and suppression of proteins in response to a stressor is disclosed. An organism exposed to a stressor, including disease caused by exposure to, e.g., a parasite, or a substance suspected of causing an adverse effect, is assayed to determine a first set of proteins expressed and a second set of proteins suppressed in response to the stressor. The amount of each protein expressed and the amount of each protein suppressed can be statistically analyzed to determine which proteins are most useful in diagnosing the stressor. A protein profile for a first stressor can be compared to protein profiles for a second stressor, a third stressor, etc. A distinct protein expression signature (PES) for the first stressor can be identified by determining subsets fo proteins expressed and/or suppressed only in response to the first stressor.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: November 25, 2003
    Assignee: University of Maryland
    Inventor: Brian P. Bradley
  • Publication number: 20030157590
    Abstract: Materials and methods for the detection of microorganisms in a sample by bioluminescence following extraction of microbial ATP, comprises adding a polyol before or during the extraction.
    Type: Application
    Filed: January 16, 2003
    Publication date: August 21, 2003
    Inventors: Nicholas Peter Martin Foote, Nigel Kyle, Brian Thomas
  • Patent number: 6605424
    Abstract: The present invention relates to a method of inhibiting desensitization of a cell to the effects of a compound. The method comprises contacting the cell with an agent capable of inhibiting phosphorylation, by a protein kinase, of a receptor for the compound present on the surface of the cell. The present invention also relates to a method of screening a compound for its ability to inhibit desensitization. The method comprises: i) contacting a receptor specific kinase-containing sample with the compound under conditions such that interaction between receptor specific kinase present in the sample and the compound can occur, and ii) determining the ability of the receptor specific kinase to phosphorylate the receptor for which it is specific.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: August 12, 2003
    Assignee: Duke University
    Inventors: Robert J. Lefkowitz, Martin J. Lohse, Jeffrey L. Benovic, Marc G. Caron
  • Patent number: 6566075
    Abstract: A DNA sequence encoding human platelet-derived growth factor receptor (hPDGF-R) has now been isolated and sequenced. An expression construct comprising the sequence encodes a receptor that can be secreted or incorporated into the membrane of a mammalian cell. The incorporated receptor is functionally equivalent to the wild-type receptor, conferring a PDGF-sensitive mitogenic response on cells lacking the receptor. The construct can be used for enhancing PDGF response of cells, determining the regions involved in transducing the signal in response to PDGF binding, providing mutated analogs and evaluating drugs for their physiologic activity.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: May 20, 2003
    Assignee: The Regents of the University of California
    Inventors: Jaime A. Escobedo, Lewis T. Williams
  • Patent number: 6555344
    Abstract: This invention belongs to the genetic engineering field, and provides the novel G protein-coupled receptor family protein SREB2 expressed in the central nervous system, genes coding for the protein, screening methods using the protein and so on. As one of the methods for obtaining the G protein-coupled receptor protein of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: April 29, 2003
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Mitsuyuki Matsumoto, Toru Sugimoto, Jun Takasaki, Masazumi Kamohara, Tetsu Saito, Masato Kobayashi
  • Patent number: 6500647
    Abstract: The present invention relates to a recombinant expression vector which is prepared by inserting a human parathyroid hormone gene containing a urokinase-specific cleavage site into an L-arabinose inducible vector containing a phosphoribulokinase gene fragment of Rhodabacter sphaeroides or its mutated gene as a fusion partner, or its mutate gene as a fusion partner, a recombinant microorganism transformed with the said expression vector, and a process for preparing human parathyroid hormone on a large scale by cultivating the said microorganism in a medium containing L-arabinose. In accordance with the invention, a recombinant human PTH having the same activity of the native human PTH can be prepared in a high yield through the precise control of induction by a manufacturing process which comprises a step of inducing expression of fusion protein in the microorganism transformed with the recombinant expression vector by L-arabinose.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: December 31, 2002
    Assignee: Mogam Biotechnology Research Institute
    Inventors: Eun-Kyung Jung, Doo-Hong Park, Soo-Il Chung
  • Patent number: 6476192
    Abstract: Antigens for the detection of antibodies to Neospora parasites for the diagnosis of neosporosis have been identified. Recombinant antigens may be produced by expression of DNA sequences derived from Neospora caninum. Both antigens are capable of detecting antibody responses in animals experimentally inoculated with N. caninum but show no evidence of cross-reactivity with serum from animals inoculated with closely related parasites such as Toxoplasma gondii or Sarcocystis species.
    Type: Grant
    Filed: April 15, 1996
    Date of Patent: November 5, 2002
    Inventors: Nicola C. Lally, Mark C. Jenkins, Jitender P. Dubey
  • Patent number: 6475728
    Abstract: An apparatus and method for identifying and/or quantifying a charged biological substance in a conductive liquid medium.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: November 5, 2002
    Assignees: Ecole Centrale de Lyon, Centre National de la Recherche Scientifique (C.N.R.S)
    Inventors: Jean-René Martin, Eliane Souteyrand
  • Patent number: 6428969
    Abstract: A method for screening substances for oncogenic activity is disclosed. The method involves administering the substance to an animal lacking responsiveness to interferon&ggr; and detecting a higher frequency or earlier time of tumor formation in the test animal compared to control animals. In addition, a method is provided for predicting the aggressiveness of a tumor in a patient.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: August 6, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Robert Schreiber, Lloyd J. Old
  • Patent number: 6423497
    Abstract: This invention relates to methods of amplifying nucleic acids to minimize contamination by products of earlier amplification reactions. More particularly, it relates to methods of using nucleic acid labels that inhibit further amplification of the amplicon, and compositions that are useful to accomplish this task. In particular, the present invention relates to photoreactive complexes of a binding ligand, a binding enhancer and a label.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: July 23, 2002
    Assignee: Applied Gene Technologies, Inc.
    Inventors: Nanibhushan Dattagupta, C. Nagaraja Sridhar, Whei-Kuo Wu
  • Patent number: 6340572
    Abstract: Methods for the isolation and identification of a toxicant in a sample are disclosed. Luminescent biological agents (i.e., bacteria) having sensitivity to a toxicant or an isolatable component in a sample are used to provide visually discernable zones of luminescent inhibition in the presence of a toxicant (or) in the presence of an isolatable sample component as separated by paper or thin layer chromatography. Kits for use in conjunction with the identification of a toxicant in a sample are also described, which include a luminescent biological reagent as the visualizing agent. Particular examples of luminescent bacterial agents useful in the practice of the present invention include Photobacterium leoganthi, Photobacterium phosphoreum, Vibrio fischeri, Vibrio harveyi a luminescent fungi, a luminescent fish extract, a luminescent dinoflagellate and fluorescent microorganisms, such as Cypridina.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: January 22, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: James E. Becvar, Laura E. Becvar
  • Publication number: 20020001821
    Abstract: Compounds which possess a complementary structure to a desired molecule, such as a biomolecule, in particular polymeric or oligomeric compounds, which are useful as in vivo or in vitro diagnostic and therapeutic agents are provided. Also, various methods for producing such compounds are provided. These polymeric or oligomeric compounds are useful in particular as antimicrobial agents, receptor, hormone or enzyme agonists and antagonists.
    Type: Application
    Filed: April 4, 2000
    Publication date: January 3, 2002
    Inventors: Klaus Mosbach, Peter A.G. Cormack, Olof Ramstrom, Karsten Haupt
  • Patent number: 6329208
    Abstract: Simple equations that relate glucose, glutamate, glucuronate, and phenylacetylglutamine 13C NMR multiplet areas to gluconeogenesis and pyruvate recycling during metabolism of [1,2,3-13C3]propionate are presented. This indicates that a direct measure of gluconeogenesis, pyruvate recycling, and anaplerosis may be obtained from a single 13C NMR spectrum of suitably prepared blood or urine samples collected after oral administration of enriched propionate, acetaminophen, and phenylacetate.
    Type: Grant
    Filed: July 16, 1998
    Date of Patent: December 11, 2001
    Assignee: Board of Regents, The University of Texas System
    Inventors: John G. Jones, A. Dean Sherry, F. M. H. Jeffrey, G. Larry Cottam, Craig. R. Malloy
  • Patent number: 6264913
    Abstract: Provided herein is a novel breath test for assessing bacterial overgrowth. The test involves administration of a labeled sorbitol or sorbitol derivative to a subject and measurement of the label in breath and/or blood.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: July 24, 2001
    Assignee: Metabolic Solutions, Inc.
    Inventor: David A. Wagner
  • Patent number: 6194161
    Abstract: A negatively-charged S. aureus antigen contains &bgr;-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing S. aureus infection.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: February 27, 2001
    Assignee: Nabi
    Inventors: Ali Ibrahim Fattom, Atulkumar Induprasad Patel
  • Patent number: 6083685
    Abstract: A method for determining the presence of retroviral RNA or DNA in a sample comprises using one or more detectable oligonucleotides that each hybridise with the primer binding site of a retroviral genome or its complement.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: July 4, 2000
    Assignee: Cambridge University Technical Services Ltd.
    Inventor: Juraj Petrik
  • Patent number: 6066446
    Abstract: Disclosed is a member comprising an interactive material which is covalently bonded to a support body by a linker material. The member can be used as a part of an assay, and the support body may include a scintillator material.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: May 23, 2000
    Assignee: NEN Life Science Products, Inc.
    Inventors: Thomas R. Mullinax, Mark N. Bobrow, Michael E. Bembenek
  • Patent number: 6057092
    Abstract: A method to follow the uptake of labeled materials into scintillant-marked compartments, cells, tissue and organelles in real time by monitoring the location of scintillant-emitted light is disclosed.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: May 2, 2000
    Assignee: Trellis Bioinformatics, Inc.
    Inventor: Lawrence M. Kauvar